Helen M Colhoun

Summary

Affiliation: University of Dundee
Country: UK

Publications

  1. pmc Use of insulin glargine and cancer incidence in Scotland: a study from the Scottish Diabetes Research Network Epidemiology Group
    H M Colhoun
    Biomedical Research Institute, University of Dundee, Mackenzie Building, Kirsty Semple Way, Dundee, DD2 4BF, Scotland, UK
    Diabetologia 52:1755-65. 2009
  2. pmc Total soluble and endogenous secretory receptor for advanced glycation end products as predictive biomarkers of coronary heart disease risk in patients with type 2 diabetes: an analysis from the CARDS trial
    Helen M Colhoun
    Medical Research Institute, University of Dundee, Dundee, U K
    Diabetes 60:2379-85. 2011
  3. ncbi Effects of atorvastatin on kidney outcomes and cardiovascular disease in patients with diabetes: an analysis from the Collaborative Atorvastatin Diabetes Study (CARDS)
    Helen M Colhoun
    Biomedical Research Institute, University of Dundee, Dundee, Scotland, UK
    Am J Kidney Dis 54:810-9. 2009
  4. pmc Genome-wide association study of genetic determinants of LDL-c response to atorvastatin therapy: importance of Lp(a)
    Harshal A Deshmukh
    University of Dundee, Dundee, United Kingdom
    J Lipid Res 53:1000-11. 2012
  5. ncbi Contemporary risk of hip fracture in type 1 and type 2 diabetes: a national registry study from Scotland
    Eleanor J Hothersall
    University of Dundee, Dundee, UK
    J Bone Miner Res 29:1054-60. 2014
  6. pmc Risk of cardiovascular disease and total mortality in adults with type 1 diabetes: Scottish registry linkage study
    Shona J Livingstone
    University of Dundee, Dundee, United Kingdom
    PLoS Med 9:e1001321. 2012
  7. pmc Levels and changes of HDL cholesterol and apolipoprotein A-I in relation to risk of cardiovascular events among statin-treated patients: a meta-analysis
    S Matthijs Boekholdt
    Departments of Cardiology S M B and Vascular Medicine B J A, G K H, J J P K, Academic Medical Center, Amsterdam, The Netherlands Center for Cardiovascular Disease Prevention, Brigham and Women s Hospital, Boston, MA S M, P M R Center of Preventive Medicine, Oslo University Hospital, Ullevål and University of Oslo, Norway T R P State University of New York Health Science Center, Brooklyn, NY J C L Rosalind Franklin University of Medicine and Science, North Chicago, IL K M A W Department of Neurology and Stroke Center, Bichat University Hospital, Paris, France P A Global Pharmaceuticals Pfizer, New York, NY D A D Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, Australia A M T Department of Biochemistry and Lipid Clinic, Royal Prince Alfred Hospital, University of Sydney, Sydney, Australia D R S NHMRC Clinical Trials Centre, University of Sydney, Sydney, Australia A K Medical Research Institute, University of Dundee, Dundee, United Kingdom H M C Centre for Diabetes, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London, United Kingdom G A H Department of Medicine, Royal Free and University College Medical School, London, United Kingdom D J B School of Biomedicine
    Circulation 128:1504-12. 2013

Collaborators

Detail Information

Publications7

  1. pmc Use of insulin glargine and cancer incidence in Scotland: a study from the Scottish Diabetes Research Network Epidemiology Group
    H M Colhoun
    Biomedical Research Institute, University of Dundee, Mackenzie Building, Kirsty Semple Way, Dundee, DD2 4BF, Scotland, UK
    Diabetologia 52:1755-65. 2009
    ..The aim of the present study was to examine whether patients with diabetes in Scotland using insulin glargine have a greater cancer risk than patients using other types of insulin...
  2. pmc Total soluble and endogenous secretory receptor for advanced glycation end products as predictive biomarkers of coronary heart disease risk in patients with type 2 diabetes: an analysis from the CARDS trial
    Helen M Colhoun
    Medical Research Institute, University of Dundee, Dundee, U K
    Diabetes 60:2379-85. 2011
    ..We examined the relationship of sRAGE and esRAGE to incident coronary heart disease (CHD) and stroke in type 2 diabetic patients followed for 3.9 years in a trial of atorvastatin: the Collaborative Atorvastatin Diabetes Study (CARDS)...
  3. ncbi Effects of atorvastatin on kidney outcomes and cardiovascular disease in patients with diabetes: an analysis from the Collaborative Atorvastatin Diabetes Study (CARDS)
    Helen M Colhoun
    Biomedical Research Institute, University of Dundee, Dundee, Scotland, UK
    Am J Kidney Dis 54:810-9. 2009
    ..We examined whether atorvastatin affects diabetic kidney disease and whether the effect of atorvastatin on cardiovascular disease (CVD) varies by kidney status in patients with diabetes...
  4. pmc Genome-wide association study of genetic determinants of LDL-c response to atorvastatin therapy: importance of Lp(a)
    Harshal A Deshmukh
    University of Dundee, Dundee, United Kingdom
    J Lipid Res 53:1000-11. 2012
    ..Therefore, an apparently lower LDL-c response to statin therapy may indicate a need for measurement of Lp(a). However, statin therapy seems beneficial even in those with high Lp(a)...
  5. ncbi Contemporary risk of hip fracture in type 1 and type 2 diabetes: a national registry study from Scotland
    Eleanor J Hothersall
    University of Dundee, Dundee, UK
    J Bone Miner Res 29:1054-60. 2014
    ....
  6. pmc Risk of cardiovascular disease and total mortality in adults with type 1 diabetes: Scottish registry linkage study
    Shona J Livingstone
    University of Dundee, Dundee, United Kingdom
    PLoS Med 9:e1001321. 2012
    ..We evaluated these risks in adults with T1DM compared with the non-diabetic population in a nationwide study from Scotland and examined control of CVD risk factors in those with T1DM...
  7. pmc Levels and changes of HDL cholesterol and apolipoprotein A-I in relation to risk of cardiovascular events among statin-treated patients: a meta-analysis
    S Matthijs Boekholdt
    Departments of Cardiology S M B and Vascular Medicine B J A, G K H, J J P K, Academic Medical Center, Amsterdam, The Netherlands Center for Cardiovascular Disease Prevention, Brigham and Women s Hospital, Boston, MA S M, P M R Center of Preventive Medicine, Oslo University Hospital, Ullevål and University of Oslo, Norway T R P State University of New York Health Science Center, Brooklyn, NY J C L Rosalind Franklin University of Medicine and Science, North Chicago, IL K M A W Department of Neurology and Stroke Center, Bichat University Hospital, Paris, France P A Global Pharmaceuticals Pfizer, New York, NY D A D Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, Australia A M T Department of Biochemistry and Lipid Clinic, Royal Prince Alfred Hospital, University of Sydney, Sydney, Australia D R S NHMRC Clinical Trials Centre, University of Sydney, Sydney, Australia A K Medical Research Institute, University of Dundee, Dundee, United Kingdom H M C Centre for Diabetes, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London, United Kingdom G A H Department of Medicine, Royal Free and University College Medical School, London, United Kingdom D J B School of Biomedicine
    Circulation 128:1504-12. 2013
    ..It is also unknown whether a rise in HDL-C or apoA-I after initiation of statin therapy is associated with a reduced cardiovascular risk...